Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020129 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2018.05.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The relationship between drug-induced immunogenicity and hypersensitivity reactions and skin tests related to infliximab, etanercept and adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis.
Turk J Med Sci
December 2024
Division of Clinical Immunology and Allergy, Department of Chest Diseases, Faculty of Medicine, Ankara University, Ankara, Turkiye.
Article Synopsis
- The study aimed to explore the connection between serum antidrug antibodies (ADAbs), hypersensitivity reactions, and local injection site reactions in patients with ankylosing spondylitis and rheumatoid arthritis who were on anti-TNF treatments.
- Sixty-nine patients with ankylosing spondylitis and 46 with rheumatoid arthritis were evaluated, measuring their drug levels, disease activity scores, and conducting skin tests to assess hypersensitivity.
- Results indicated a significant link between hypersensitivity reactions (both immediate and local) and the intradermal tests in patients taking anti-TNF drugs, particularly with adalimumab and etanercept.
Promising Use of the New Biologics in the Management of Drug-Induced Hypersensitivity Reactions: Preliminary Approaches.
Endocr Metab Immune Disord Drug Targets
September 2021
Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
Biologics are an innovative class of drugs that can selectively influence immunological responses at a cellular level. Although their use is usually restricted to some specific diseases, such as autoimmune pathologies and tumors, their "off-label" administration has increased widely in the last years. Drug treatment may induce hypersensitivity reactions which currently lack any gold standard therapy but maybe a future field of application for biologics.
View Article and Find Full Text PDFImmediate-type infliximab infusion reaction presenting as purpura.
JAAD Case Rep
July 2018
Department of Dermatology, UC Davis Medical Center, Sacramento, California.
Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab.
Arch Dermatol
September 2008
Department of Dermatology, University of Maryland, Baltimore, MD 21201, USA.
Background: Tumor necrosis factor (TNF) inhibitors such as adalimumab, etanercept, and infliximab play an increasingly important role in the management of a variety of chronic inflammatory disorders. With their increasing use, a wide spectrum of dermatological adverse effects, including injection site reactions and the development of dermatitis, have been recognized. Previous studies have implicated the role of the delayed-type hypersensitivity reaction in mediation of injection site reactions to etanercept.
View Article and Find Full Text PDFLow-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.
Ann Rheum Dis
November 2007
Department of Rheumatology, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden.
Background And Objective: Treatment-limiting infusion reactions to infliximab have not been fully explained in rheumatoid arthritis patients. Our main objective is to investigate the role of daily oral glucocorticoids use on such reactions.
Method: Forty-three patients with immediate-type infusion reactions were identified in a large registry-based cohort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!